home / stock / apvo / apvo news

APVO News and Press, Aptevo Therapeutics Inc. From 03/29/22

Stock Information
Company Name: Aptevo Therapeutics Inc.
Stock Symbol: APVO
Market: NASDAQ
Website: aptevotherapeutics.com
Menu
APVO APVO Quote APVO Short APVO News APVO Articles APVO Message Board
Get APVO Alerts

News, Short Squeeze, Breakout and More Instantly...
APVO - SAN, STLA and EPAM among pre market gainers

Guardforce AI (GFAI) +46% is expanding it footprint by establishing subsidiaries in Dubai and Australia. IGM Biosciences (IGMS) +32% on proposed stock offering. Hycroft Mining Holding (HYMC) +23% GameStop, AMC and Bed Bath pull off a meme stock comeback. Nielsen Holdi...
APVO - Aptevo Therapeutics Announces Monotherapy Patient Received a Transplant in APVO436 Expansion Trial for the Treatment of Acute Myeloid Leukemia

Patients in Both Monotherapy and Combination Arms in Multi-Cohort Trial Have Achieved Transplant Eligible Status SEATTLE, WA / ACCESSWIRE / March 29, 2022 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therape...

APVO - KNDI, LILM and ADN among mid- day movers

Gainers: JX Luxventure Limited (LLL) +43%. Alpha Tau Medical (DRTS) +37%. Takung Art (TKAT) +31%. Emclaire Financial (EMCF) +32%. BiondVax (BVXV) +30%. Mercurity Fintech Holding (MFH) +26%. INmune Bio (INMB) +19%. Gracell (GRCL) +21%. Aptevo (APVO) +21%. Lilium (LILM) +20%. LiqTech Internatio...

APVO - Aptevo climbs as 2021 revenue more than doubles

The shares of clinical-stage biotech, Aptevo Therapeutics (NASDAQ:APVO +24.2%) have reached over a two-after recording the biggest intraday gain since November as the investors react to the company’s better-than-expected financials for 2021. Revenue for the period rose ~185% YoY to $12...
APVO - BiondVax, Alpha Tau top healthcare gainers; Sonendo, Creative Medical among losers

Gainers: BiondVax Pharmaceuticals (BVXV) +39%. Alpha Tau Medical (DRTS) +38%. CollPlant Biotechnologies (CLGN) +10%. Aptevo Therapeutics (APVO) +8%. HOOKIPA Pharma (HOOK) +8%. Losers: Sonendo (SONX) -11%. Creative Medical Technology (CELZ) -9%. Lan...

APVO - Aptevo Therapeutics GAAP EPS of -$6.07 beats by $0.07, revenue of $12.29M beats by $0.26M

Aptevo Therapeutics press release (NASDAQ:APVO): FY GAAP EPS of -$6.07 beats by $0.07. Revenue of $12.29M (+185.2% Y/Y) beats by $0.26M. Cash and cash equivalents as of December 31, 2021 totaling $46.3 million, including restricted cash of $1.3 million Shares +7.25% PM. For further details ...

APVO - Aptevo Therapeutics Reports 2021 Financial Results and Provides Business Update

SEATTLE, WA / ACCESSWIRE / March 24, 2022 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today reported its fina...
APVO - Doximity, Aptevo top healthcare gainers; Varex Imaging, BioCardia among losers

Gainers: Doximity (NYSE:DOCS) +20%. Aptevo Therapeutics (NASDAQ:APVO) +17%. Biofrontera (NASDAQ:BFRA) +14%. Karyopharm Therapeutics (NASDAQ:KPTI) +14%. Teva Pharmaceutical (NYSE:TEVA) +9%. Losers: Varex Imaging (NASDAQ:VREX) -11%. BioCardia (NASDAQ...

APVO - Aptevo Therapeutics receives $10M in non-dilutive milestone payment on RUXIENCE sales

Aptevo Therapeutics (NASDAQ:APVO) trades 5.8% higher premarket after the company earned $10M non-dilutive milestone payment related to 2021 sales of RUXIENCE; this is under its royalty purchase agreement with HealthCare Royalty Management. The milestone will be used to pay down...

APVO - Aptevo Therapeutics Earns $10 Million Non-Dilutive Milestone Payment on Sales of RUXIENCE, Provides Company Update

APVO436 Phase 1b Trial for Acute Myeloid Leukemia Adds New Site Complete Remission Patient to Advance to Transplant SEATTLE, WA / ACCESSWIRE / February 9, 2022 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on de...
Previous 10 Next 10